Pamifos (Pamidronate Disodium)

Pamidronate disodium, the active ingredient in Pamifos, is a bisphosphonate presented as a intravenous solution for intravenous use. It is used to manage bone resorption conditions such as hypercalcemia of malignancy and skeletal complications of cancer. GNH USA supplies Pamifos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Pamifos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Pamifos ​​​​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​  acts ​ ​ ​  on ​ ​  bone ​ ​  resorption pathways ​ ​  and ​ ​  is ​ ​  indicated ​ ​  for: - Hyper‑  ​ ​ ​ ​ ​ ​  calcemia of malignancy: reduces serum calcium levels. - Bone  ​ ​ ​ ​ ​ ​  metastases from solid tumours: helps prevent skeletal‑related events. - Paget’s disease of bone: normalises bone turnover. - Osteolytic lesions in multiple myeloma: decreases bone loss. - Osteoporosis (off‑label in some regions): supports bone density maintenance.

Pamifos may cause a range of adverse reactions, most of which are dose‑related and infusion‑associated.

Common Side Effects: - Flu‑like symptoms: fever, chills, myalgia. - Musculoskeletal pain: bone or joint discomfort. - Nausea or vomiting. - Transient elevation of serum creatinine. - Injection site reactions: erythema or discomfort.

Serious or Rare Side Effects: - Acute renal failure: sudden loss of kidney function. - Severe hypocalcaemia: dangerously low calcium levels. - Osteonecrosis of the jaw (ONJ): exposed bone in the oral cavity. - Atypical femoral fractures: stress fractures of the femur. - Anaphylactic reactions: severe allergic response requiring immediate care.

Before initiating Pamifos therapy, clinicians should evaluate renal function, calcium status, and concomitant medications.

- Renal monitoring: assess serum creatinine and eGFR before each dose. - Calcium supplementation: ensure adequate calcium and vitamin D intake. - Concomitant nephrotoxins: avoid or adjust dosing of other renal‑impairing agents. - Dental health: perform dental examination and treat infections before therapy. - Pregnancy and lactation: use only if clearly needed; discuss risks with a specialist. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Pamifos can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aminoglycoside antibiotics: increase risk of nephrotoxicity. - Loop diuretics (e.g., furosemide): may exacerbate hypocalcaemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can affect renal clearance. - Corticosteroids: may potentiate bone loss if not monitored. - Calcium‑containing antacids: reduce pamidronate absorption if given concurrently.